Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4607]

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after breast-conserving surgery

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after...

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for immune cell therapy of solid cancer

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for...

$FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation$

FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation

How AI found the words to kill cancer cells

How AI found the words to kill cancer cells

P53 could be key to therapies for salivary gland cancer

P53 could be key to therapies for salivary gland cancer

SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes

SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and...

SABCS 2022: Treatment decision guided by CTC count may improve long-term outcomes for mBC

SABCS 2022: Treatment decision guided by CTC count may improve long-term outcomes for mBC

SABCS 2022: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer

SABCS 2022: Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer

More from ecancer